Russell Investments Group Ltd. Purchases Shares of 27,042 Aldeyra Therapeutics, Inc. $ALDX

Russell Investments Group Ltd. purchased a new stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in the 1st quarter, according to its most recent filing with the SEC. The fund purchased 27,042 shares of the biotechnology company’s stock, valued at approximately $155,000.

Several other institutional investors also recently bought and sold shares of ALDX. Barclays PLC raised its holdings in Aldeyra Therapeutics by 14.9% in the 4th quarter. Barclays PLC now owns 75,330 shares of the biotechnology company’s stock valued at $376,000 after acquiring an additional 9,769 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Aldeyra Therapeutics by 21.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 735,763 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 131,722 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth $52,000. Northern Trust Corp increased its holdings in shares of Aldeyra Therapeutics by 4.3% during the 4th quarter. Northern Trust Corp now owns 405,517 shares of the biotechnology company’s stock worth $2,024,000 after buying an additional 16,894 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth $56,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Trading Down 1.5%

Shares of Aldeyra Therapeutics stock opened at $5.75 on Wednesday. The company has a fifty day moving average price of $5.07 and a 200 day moving average price of $4.24. The stock has a market cap of $344.43 million, a price-to-earnings ratio of -6.76 and a beta of 0.80. Aldeyra Therapeutics, Inc. has a twelve month low of $1.14 and a twelve month high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Analysts forecast that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ALDX shares. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Monday, May 19th. Wall Street Zen upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 21st. Finally, Zacks Research upgraded Aldeyra Therapeutics to a “hold” rating in a report on Friday, August 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.50.

Insiders Place Their Bets

In other Aldeyra Therapeutics news, insider Stephen Machatha sold 22,073 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $5.15, for a total value of $113,675.95. Following the completion of the transaction, the insider directly owned 221,799 shares of the company’s stock, valued at $1,142,264.85. This represents a 9.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.50% of the stock is currently owned by insiders.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.